TrialNature medicine2026

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

Tuan Vu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.